Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics (VIRX)
OTHER OTC:VIRX
VIRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $1.31
Previous CloseN/A
Volume1.67M
Average Volume (3M)383.36K
Market Cap
$1.06M
Enterprise Value$4.94M
Total Cash (Recent Filing)$24.81M
Total Debt (Recent Filing)$7.26M
Price to Earnings (P/E)―
Beta-0.75
Next Earnings
May 07, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding39,744,220
10 Day Avg. Volume251,109
30 Day Avg. Volume383,364
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.03
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$0.25Price Target Upside733.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Viracta Therapeutics News
PremiumPre-Earnings
Is VIRX a Buy, Before Earnings?
PremiumCompany Announcements
Viracta Therapeutics Announces Wind-Down and Leadership Changes
PremiumCompany Announcements
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
---
Ownership Overview
2.48% Insiders
1.25% Mutual Funds
0.68% Other Institutional Investors
94.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIRX FAQ
What was Viracta Therapeutics’s price range in the past 12 months?
Viracta Therapeutics lowest stock price was <$0.01 and its highest was $1.31 in the past 12 months.
What is Viracta Therapeutics’s market cap?
Viracta Therapeutics’s market cap is $1.06M.
When is Viracta Therapeutics’s upcoming earnings report date?
Viracta Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 41 days.
How were Viracta Therapeutics’s earnings last quarter?
Currently, no data Available
Is Viracta Therapeutics overvalued?
According to Wall Street analysts Viracta Therapeutics’s price is currently Undervalued.
Does Viracta Therapeutics pay dividends?
Viracta Therapeutics does not currently pay dividends.
What is Viracta Therapeutics’s EPS estimate?
Viracta Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Viracta Therapeutics have?
Viracta Therapeutics has 39,744,220 shares outstanding.
What happened to Viracta Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Viracta Therapeutics?
Currently, no hedge funds are holding shares in VIRX
---
Company Description
Viracta Therapeutics
Viracta Therapeutics, Inc. (VIRX) is a precision oncology company focused on developing targeted therapies for virus-associated cancers. The company's core product pipeline is centered around its proprietary drug candidates that are designed to selectively target and inhibit the viral proteins associated with certain cancer types, thereby enhancing the effectiveness of cancer treatment. Viracta's lead clinical program is aimed at treating Epstein-Barr virus (EBV)-associated malignancies, leveraging its novel approach to provide more effective treatment options for patients.
---
VIRX Stock 12 Month Forecast
Average Price Target
$0.25
▲(733.33% Upside)
Technical Analysis
Best Analysts Covering VIRX
1 Year
1 Year Success Rate
1/23 ratings generated profit
1 Year Average Return
-60.56%
reiterated a buy rating 10 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 4.35% of your transactions generating a profit, with an average return of -60.56% per trade.
---